Stockreport

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Corporation  (XOMA) 
Last xoma royalty corporation earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.xoma.com/investor-relations
PDF MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA [Read more]